The introduction of cisplatin-based chemotherapy into clinical practice has resulted in a substantial improvement of relapse-free and long-term survival of patients with testicular germ cell tumors. Late relapse (LR) of testicular cancer has recently been described as a unique entity. It is currently defined as tumor recurrence more than 2 years after complete remission following primary treatment, including chemotherapy. The incidence ranges from 2 to 6%, with a median relapse-free interval of 5.4-7.1 years from the initial treatment. Authors report a case of nonseminomatous germ cell tumor of the testis that recurred 15 years after the completion of first-line therapy. Though a few such late relapses have been observed, this condition remains extremely rare. Although the majority of recurrences are encountered in the first 2 years after treatment and later recurrences are rare, their time-course and pattern have implications for long-term follow-up. [Turk J Cancer 2008;38(4):190-193]